PPA
UBX

Parametric Portfolio Associates’s Unity Biotechnology UBX Stock Holding History

Parametric Portfolio Associates’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,140
Closed -$146K – 3662
2021
Q2 		$146K Sell
3,140
-1,387
-31% -$66.8K ﹤0.01% 3453
2021
Q1 		$272K Sell
4,527
-42
-0.9% -$2.86K ﹤0.01% 3752
2020
Q4 		$239K Buy
4,569
+1,755
+62% +$84.6K ﹤0.01% 3700
2020
Q3 		$97K Sell
2,814
-3,175
-53% -$201K ﹤0.01% 3802
2020
Q2 		$520K Buy
+5,989
New +$444K ﹤0.01% 3256
2020
Q1 		– Sell
-1,008
Closed -$73K – 4013
2019
Q4 		$73K Buy
+1,008
New +$71.1K ﹤0.01% 3898

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Parametric Portfolio Associates's UBX Position: Q3 2021 in Review

Parametric Portfolio Associates sold out of Unity Biotechnology (UBX) in Q3 2021, closing a stake of 3,140 shares — an estimated $146K sold.

Parametric Portfolio Associates first reported a position in UBX in Q4 2019 and held it in 6 quarters. The position peaked at $520K in Q2 2020. 84 funds tracked by Wall St. Rank hold UBX as of Q3 2021.

  • Parametric Portfolio Associates reported no remaining Unity Biotechnology position as of Q3 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 3,140 Unity Biotechnology shares in Q3 2021, an estimated $146K.
  • Parametric Portfolio Associates first reported a position in Unity Biotechnology in Q4 2019 and held it in 6 quarters.
  • Parametric Portfolio Associates's Unity Biotechnology position peaked at $520K in Q2 2020.
  • 84 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2021.

Based on Parametric Portfolio Associates's 13F filing for Q3 2021, filed 15 Nov 2021.